Previous Page  3 / 10 Next Page
Information
Show Menu
Previous Page 3 / 10 Next Page
Page Background

Volume 08

Journal of Alzheimers Disease & Parkinsonism

Alzheimer's Congress 2018

May 30-31, 2018

Page 12

Notes:

conference

series

.com

May 30-31, 2018 Osaka, Japan

10

th

World Congress on

Alzheimer's Disease & Dementia

Adult neurogenesis stimulation as an anti-alzheimer’s disease therapeutic approach

S

ox2 is a transcription factor that controls the balance between stem cells self-renewal and differentiation, thereby

contributing to the control of neurogenesis. Importantly, Sox2 deficiency triggers neurodegeneration in the adult brain.

Moreover, Sox2 co localizes with the Amyloid Precursor Protein (APP) in stem cells and Sox2 levels are decreased in the

brain of Alzheimer’s Disease (AD) patients. We have recently reported the existence of functional network engaging Sox2, the

APP Intracellular Domain AICD and the secretase ADAM10

in vitro

in human cells. Indeed, Sox2 is a potent activator of the

non-amyloidogenic processing of APP by increasing the expression of ADAM10. Secondly, transient overexpression of the

pro-apoptotic C-terminal APP-derived AICD50 metabolite reduces Sox2 transcription whereas inhibiting AICD production

with a -secretase inhibitor augments Sox2 expression, and consequently ADAM10 protein levels, in HEK293 and SH-SY5Y

cell lines. Experiments carried out

in vivo

indicate that Sox2 levels are diminished in the hippocampus of mouse models of AD

when compared to control animals. Whether ADAM10 and Sox2 co-localize in neurogenic areas of the adult mouse brain and

determining if this co-localization is impaired in transgenic AD models is currently under investigation. Finally, the impact

of the pharmacological or the genetic modulation of this network on the reprogramming of human induced pluripotent stem

cells into neurons is currently monitored in an

in vitro

model of neurogenesis. Altogether, our data suggest that enhancing the

Sox2/ADAM10 axis may favor neuroprotection and neurogenesis during the development of AD.

Biography

Bruno Vincent has completed his PhD from the University of Nice, France in 1996. He has then joined the Rockefeller University in New York as a Postdoctoral

Fellow. He returned back to France in 1999 at the Institute of Molecular and Cellular Pharmacology in Sophia-Antipolis and took the position of permanent

Researcher at the National Center for Scientific Research (CNRS) in 2001 and was promoted to Research Director. In 2010, he moved to Mahidol University

in Bangkok where his research team is working on the identification of new AD-regulating factors. He has published 60 articles in reputed international journals.

bruno.vin@mahidol.ac.th

Bruno Vincent

Mahidol University, Thailand

Bruno Vincent, J Alzheimers Dis Parkinsonism 2018, Volume 8

DOI: 10.4172/2161-0460-C4-044